Rheumatology Network's Top 5: March 12 2021

March 12, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

Tocilizumab Approved by the FDA for Systemic Sclerosis-Associated Interstitial Lung Disease

Subcutaneous injection of tocilizumab has been shown to improve the rate of lung function in patients with systemic sclerosis-induced interstitial lung disease when compared with a placebo.

Click the image to view this story.

Patients With Rheumatoid Arthritis Report Inconsistent Medicare Claims History

Older adults who self-report rheumatoid arthritis (RA) do not have a Medicare claims history consistent with their diagnosis, according to study.

Click the image to view this story.

Upadacitinib Shows Efficiency in Psoriatic Arthritis Refractory to Biologics

In patients with psoriatic arthritis refractory or intolerant to biologic disease-modifying antirheumatic drugs (DMARDs), upadacitinib (Abbvie; Rinvoq) 15 mg and 30 mg once per day was more effective than placebo over 24 weeks in improving signs and symptoms of psoriatic arthritis.

Click the image to view this story.

Haunted by the Past: Adverse Childhood Experiences and RA

Research suggests that adults who experienced 2 or more traumatic events during childhood are at a 100% increased risk to develop rheumatic disease.

Click the image to view this story.

Patients with Anti-Sjögren’s Syndrome Type A (Anti-SSA) Have Higher Risk of Neurological Involvement

There were no differences in the occurrence of clinical characteristics between the subset of patients with and without neurological involvement, however disease activity was slightly higher in patients with neurological involvement than those without. Additionally, anti-SSA antibody was significantly higher in patients with neurological involvement and anti-SSB autoantibody was lower.

Click the image to view this story.